All In Biotech

NDA 019557 · Onesource Specialty

Vepesid

Etoposide · Oral · Topoisomerase Inhibitor

Priority review

Last checked: Nov 19, 2026Latest source record: Nov 5, 2002 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Dec 30, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,914

435 Phase 3, 235 recruiting

FAERS reports

74,497

72,510 serious, 18,093 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

Warnings VePesid (etoposide) should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Severe myelosuppression with resulting infection or bleeding may occur.

What it is approved for

From the label in effect Sep 9, 2026.

INDICATIONS AND USAGE VePesid (etoposide) is indicated in the management of: Small Cell Lung Cancer —Etoposide capsules in combination with other approved chemotherapeutic agents as first line treatment in patients with small cell lung cancer.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 30, 1986 Original approval · Type 3 - New Dosage Form · priority review
2 products under this application
  • VEPESID · ETOPOSIDE 50MG · CAPSULE, ORAL · Prescription · TE AB
  • VEPESID · ETOPOSIDE 100MG · CAPSULE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Etoposide" as an intervention, any sponsor and status, largest first.

All 1,914 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use8,484
  • febrile neutropenia7,820
  • neutropenia5,139
  • drug ineffective4,782
  • disease progression4,583
  • thrombocytopenia4,175
  • pyrexia3,494
  • anaemia3,404
  • sepsis3,065
  • product use in unapproved indication3,008
  • death2,870
  • pancytopenia2,823

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004868
2005950
2006813
20071,042
20081,136
20091,098
20101,218
20111,865
20122,074
20131,625
20141,736
20152,307
20162,628
20173,684
20184,701
20194,937
20205,884
20215,854
20226,644
20237,020
20246,534
20255,651
20264,224

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,084 on PubMed

Sponsor: Onesource Specialty

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.